Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Clarus Therapeutics Holdings Inc
Additional Paid In Capital
Clarus Therapeutics Holdings Inc
Additional Paid In Capital Peer Comparison
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
Additional Paid In Capital
$305.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Additional Paid In Capital
$45.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
85%
|
CAGR 10-Years
41%
|
|
Pfizer Inc
NYSE:PFE
|
Additional Paid In Capital
$93B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Merck & Co Inc
NYSE:MRK
|
Additional Paid In Capital
$44.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Additional Paid In Capital
$7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is Clarus Therapeutics Holdings Inc's Additional Paid In Capital?
Additional Paid In Capital
305.7m
USD
Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Additional Paid In Capital amounts to 305.7m USD.